Increased fMRI food cue reactivity in obesity, i.e. higher responses to high- vs. low-calorie food images, is a promising marker of the dysregulated brain reward system underlying enhanced susceptibility to obesogenic environmental cues. Recently, it has also been shown that weight loss interventions might affect fMRI food cue reactivity and that there is a close association between the alteration of cue reactivity and the outcome of the intervention. Here we tested whether fMRI food cue reactivity could be used as a marker of diet-induced early changes of neural processing in the striatum that are predictive of the outcome of the weight loss intervention. To this end we investigated the relationship between food cue reactivity in the striatum measured one month after the onset of the weight loss program and weight changes obtained at the end of the six-month intervention. We observed a significant correlation between BMI change measured after six months and early alterations of fMRI food cue reactivity in the striatum, including the bilateral putamen, right pallidum, and left caudate. Our findings provide evidence for diet-induced early alterations of fMRI food cue reactivity in the striatum that can predict the outcome of the weight loss intervention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463125PMC
http://dx.doi.org/10.1016/j.nicl.2019.101803DOI Listing

Publication Analysis

Top Keywords

cue reactivity
32
food cue
28
fmri food
24
weight loss
20
reactivity striatum
16
loss intervention
12
early alterations
12
alterations fmri
12
food
8
cue
8

Similar Publications

Characterization of serum and brain cytokine levels following prolonged binge-like methamphetamine self-administration and cued methamphetamine seeking.

J Neuroimmunol

January 2025

Department of Psychology, Arizona State University, Tempe, AZ 85257, USA; Interdisciplinary Graduate Program in Neuroscience, School of Life Sciences, Arizona State University, Tempe, AZ 85257, USA. Electronic address:

Methamphetamine (METH) use is associated with peripheral and brain inflammation that can contribute to METH-associated toxicity and heightened cue reactivity. However, the persistence of these phenomena, especially with regards to changes in brain proinflammatory cytokine levels, is not yet clear. In this study, we determined the effects of repeated binge-like METH self-administration (96-h/week for 3 weeks) followed by cued drug seeking for up to 60 days into abstinence in male and female rats.

View Article and Find Full Text PDF

Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone.

Psychopharmacology (Berl)

January 2025

Edith Collins Centre for Translational Research in Alcohol, Drugs and Toxicology, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, NSW, Australia.

Rationale: Both topiramate and naltrexone have been shown to affect neural alcohol cue reactivity in alcohol use disorder (AUD). However, their comparative effects on alcohol cue reactivity are unknown. Moreover, while naltrexone has been found to normalize hyperactive localized network connectivity implicated in AUD, no studies have examined the effect of topiramate on intrinsic functional connectivity or compared functional connectivity between these two widely used medications.

View Article and Find Full Text PDF

Objective: In this study, we examine the network structure of posttraumatic stress disorder (PTSD), including core symptoms and strong edges in patients undergoing chemotherapy for colorectal cancer in China, and lay the groundwork for targeted psychological interventions for these patients.

Methods: This study included 360 colorectal cancer patients receiving chemotherapy at a third-class hospital in Wuxi, China, from November 2023 to June 2024. The severity of each item of PTSD was assessed using the DSM-5 Checklist (PCL-5).

View Article and Find Full Text PDF

Aims: We evaluated the safety, efficacy, and patient adherence to oral ANS-6637, a selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2), for treating alcohol use disorder (AUD).

Methods: A 3-arm, double-blind, randomized, proof-of-concept human laboratory study embedded in a 5-week multisite clinical trial tested 200 mg and 600 mg daily doses of ANS-6637 compared to placebo in treatment-seeking adults with AUD. After 1 week of medication, participants completed an alcohol cue reactivity session.

View Article and Find Full Text PDF

Introduction: Prior research shows that in-person exposure to electronic nicotine delivery systems (ENDS) use increases desire for cigarettes and ENDS. However, less is known about the impact of cues delivered during remote interactions. This study extends previous in-person cue work by leveraging a remote confederate-delivered cue-delivery paradigm to evaluate the impact of dual nicotine vaping (vs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!